Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials

Fig. 2

Change from baseline in DAS28-CRP (a), CDAI (b) and SDAI (c) at weeks 30/54. CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, 28-joint Disease Activity Score based on C-reactive protein; IV, intravenous; SDAI, Simple Disease Activity Index; SC, subcutaneous; SD, standard deviation. *CT-P13 IV vs CT-P13 SC p < 0.05, CT-P13 SC vs reference infliximab IV p < 0.05 and CT-P13 IV vs reference infliximab IV p ≥ 0.05. p-values derive from the meta-regression efficacy analysis of week-30 and week-54 data (Tables 3 and 4)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us